Corvus Pharmaceuticals, Inc.
Symbol: CRVS (NASDAQ)
3.72
▲ (2.91%) 0.105
Company Description:
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Key Stats
- Today's Open: $3.56
- Today's High: $3.9
- Today's Low: $3.521
- Today's Volume: 713.95K
- Yesterday Close: $3.61
- Yesterday High: $3.77
- Yesterday Low: $3.5
- Yesterday Volume: 1.05M
- Last Min Volume: 0
- Last Min High: $3.715
- Last Min Low: $3.714
- Last Min VWAP: $0
Company Profile
- Name: Corvus Pharmaceuticals, Inc.
- Website: https://www.corvuspharma.com
- Listed Date: 2016-03-23
- Location: BURLINGAME, CA
- Market Status: Active
- CIK Number: 0001626971
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $312.70M
- Round Lot: 100
- Outstanding Shares: 77.11M
- Asset Type: CS
RECENT FILINGS FOR CRVS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-14 | SCHEDULE 13D/A | View |
| 2025-05-09 | 4 | View |
| 2025-05-08 | S-8 | View |
| 2025-05-08 | 10-Q | View |
| 2025-05-08 | 8-K | View |
| 2025-05-01 | SCHEDULE 13D/A | View |
| 2025-04-25 | DEFA14A | View |
| 2025-04-25 | DEF 14A | View |
| 2025-04-09 | 4 | View |
| 2025-04-09 | 3 | View |
| 2025-04-09 | 8-K | View |
| 2025-03-25 | 10-K | View |
| 2025-03-25 | 8-K | View |
| 2025-02-14 | SCHEDULE 13G/A | View |
| 2025-02-13 | SCHEDULE 13G/A | View |
| 2025-01-13 | 8-K | View |
| 2024-12-23 | 4 | View |
| 2024-12-23 | 4 | View |
| 2024-12-23 | 4 | View |
Latest News on CRVS